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Abstract: The importance of renin-angiotensin-aldosterone system (RAAS) in diseases such as 
hypertension, congestive heart failure and chronic renal failure has long ago been recognized. It 
has also been established that inhibition of RAAS, using inhibitors of the angiotensin-converting 
enzyme (ACE) or angiotensin II receptor blockers (ARB), is an effective way to intervene with 
the pathogenesis of these disorders. Renin inhibitors block the RAAS at the highest level, at its 
origin, and might thus offer a new exciting approach for pharmacotherapy of arterial hyperten-
sion. Aliskiren is the ﬁ  rst in a new class of orally active, non-peptide, low molecular weight renin 
inhibitors, and so far the only renin inhibitor that has progressed to phase III clinical trials. This 
review summarizes the available data on the pharmacokinetic and pharmacodynamic properties 
of aliskiren and its clinical development for treatment of arterial hypertension.
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Introduction
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the regulation 
of blood pressure (BP) and volume homeostasis. Its importance in diseases such as 
hypertension, congestive heart failure and chronic renal failure has long ago been 
recognized and it has also been established that inhibition of RAAS is an effective 
way to intervene with the pathogenesis of these disorders (Ruggenenti et al 1999; 
Flather et al 2000; Turnbull 2003).
Secretion of renin is the ﬁ  rst step in RAAS cascade and, importantly, also the 
rate-limiting step (Skeggs et al 1957). Renin is secreted, in response to a variety of 
stimuli, from the juxtaglomerular cells in the kidneys. The only known physiological 
substrate for renin in the plasma is angiotensinogen. Renin cleaves angiotensinogen 
to form the inactive decapeptide angiotensin I (Ang I) which is then converted by 
angiotensin-converting enzyme (ACE) to the active octapeptide Ang II, the effector 
enzyme of the cascade. Ang II interacts with type-1 angiotensin receptors (AT-1), 
inducing vasoconstriction and increase in blood pressure, promoting adrenal aldo-
sterone secretion, renal sodium reabsoption and release of catecholamines from the 
adrenal medulla and prejunctional nerve endings (Kim and Iwao 2000).
RAAS may be blocked by pharmacological agents at various sites. Inhibitors of 
the ACE block the formation of Ang II but also cause a respective increase in the 
concentrations of Ang I that can subsequently be converted to Ang II by other path-
ways, such as the chymase system. Also, ACE inhibitors are not speciﬁ  c for RAAS, 
preventing inactivation of bradykinin and substance P that are known to mediate some 
of the side-effects of ACE inhibitions such as cough and angioedema. Angiotensin-II 
receptor blockers (ARBs) speciﬁ  cally block the AT-1 receptors (Brunner et al 1974), Vascular Health and Risk Management 2007:3(6) 810
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leaving the other types of AT receptors (eg, AT2R and AT4R) 
that might be involved in some important regulatory func-
tions of the endothelium, unopposed to potential stimulation 
by Ang II (Watanabe et al 2005). Importantly, along with 
the incomplete blockade of RAAS, both ACE inhibitors and 
ARBs lead to a substantial compensatory raise in the circulat-
ing active renin and angiotensin peptides that may eventually 
limit their therapeutic potential (Stanton 2003).
Renin is the rate-limiting step of the RAAS and has 
unique speciﬁ  city for its substrate, angiotensinogen. Inhibi-
tion of renin has long ago been recognised as an attractive 
option that would block the RAAS at the highest level, at 
its origin. Thus, the formation of both Ang I and Ang II is 
blocked, there is no activation of the AT receptors and no 
interference with bradykinin metabolism. It has been shown 
that a rise in circulating renin occurs, but the activity of the 
released enzyme is blocked in the presence of renin inhibitors 
(Nussberger et al 2002; Azizi et al 2004).
The ﬁ  rst renin inhibitors were synthesized already more 
than 30-years ago (Gross et al 1971). First orally active 
compounds were developed in the 1980s, including enalkiren 
(A 64662; Abbott, Abbott Park, IL, USA), CGP38560A 
(Ciba-Geigy, Basel, Switzerland), remikiren (Ro 425892; 
Hoffmann-La Roche, Basel, Switzerland), and zankiren 
(A 72517; Abbott). However, poor absorption from the gas-
trointestinal tract (with bioavailability of less than 2%), short 
half-life and low potency prevented further development of 
these compounds (Staessen et al 2006).
Aliskiren is the ﬁ  rst in a new class of orally active, non-
peptide, low molecular weight renin inhibitors, and so far the 
only renin inhibitor that has progressed to phase III clinical 
trials. Aliskiren (formerly CGP 60536) was discovered in 
Ciba-Geigy (now Novartis, Basel, Switzerland) through a 
combination of molecular modeling and crystallographic 
structure analysis (Wood et al 2003). The synthetic pathway 
at that time was not suitable for large-scale manufacturing 
and the compound was out-licenced to Speedel AG (Basel, 
Switzerland) where a new cost-effective manufacturing 
method for aliskiren (SPP 100) was developed and preclinical 
and early clinical testing successfully performed. Novartis 
exercised its call-back option for further development of 
aliskiren in phase III trials (Wood et al 2003). Aliskiren was 
approved in 2007 by regulatary bodies both in Europe and in 
the US, for use alone as with others agents in the treatment 
of arterial hypertension.
This review summarizes the available data on the pharma-
cokinetic and pharmacodynamic properties of aliskiren and its 
clinical development for treatment of arterial hypertension.
Pharmacokinetic properties
Aliskiren is a transition-state mimetic, with favourable 
physico-chemical properties including high aqueous solubility 
(350 mg/ml at pH 7.4) and high hydrophilicity (log Poct/
water = 2.45 at pH 7.4). These properties are important prereq-
uisites for improved oral bioavailability (Wood et al 2003).
Aliskiren pharmacokinetics has been studied in marmosets. 
After a single oral dose of 10 mg/kg, peak plasma concentra-
tions were reached in 1–2 hours. The calculated bioavailability 
was 16.3% and mean half-life 2.3 h (Wood et al 2005).
The single and multiple-dose oral pharmacokinetics 
of aliskiren have been investigated over the dose range 
40–1800 mg in healthy male subjects (Azizi et al 2006). 
Study in healthy volunteers (n = 18) showed that the plasma 
concentration increased dose-dependently after oral aliskiren 
in doses of 40–640 mg/day, with peak concentrations reached 
in 3–6 h. The mean plasma half-life was 23.7 h (with SD 
of 7.6h and range 20–45 h). The oral bioavailability of the 
hard gelatine 75 mg capsule was 2.6%. Plasma steady-state 
concentrations were reached after 5–8 days of treatment 
(Nussberger et al 2002).
Aliskiren accumulates following multiple once-daily 
administration as indicated by the accumulation ratios of 
between 1.4 and 3.9, with the accumulation being more 
pronounced at higher doses (Azizi et al 2006). Aliskiren 
pharmacokinetics is dependent on food intake. Thus, aliskiren 
150 mg orally with food results in mean Cmax and AUC0–∞ 
values by 81 and 62% lower, respectively, when compared 
to the fasting state (Azizi et al 2006).
Aliskiren pharmacokinetics after a single dose of 300 mg 
has been examined in type-2 diabetic patients (n = 30) versus 
healthy volunteers (n = 30) and no signiﬁ  cant differences 
were observed. Also, no signiﬁ  cant correlation between 
glycaemic control (% glycosylated haemoglobin) and any 
of the measured pharmacokinetic parameters were detected 
(Zhao et al 2006).
Aliskiren demonstrated similar pharmacokinetic and 
pharmacodynamic properties in Japanese and Caucasian 
subjects (Vaidyanathan, Jermany et al 2007). At steady state, 
peak PRC level and AUC for the concentration-time plot 
were not signiﬁ  cantly different (p = 0.64 and p = 0.80, respec-
tively) and PRA was reduced to a similar extent (by 87.5% 
and 85.7%, respectively, compared with baseline; p  0.01). 
Aliskiren was well tolerated by both ethnic groups.
Aliskiren is mainly eliminated unmetabolized via biliary 
excretion, with less than 1% excreted in the urine (de Gasparo 
et al 1989). Aliskiren binds only moderately to plasma 
proteins (mean protein-bounding level of 49.5%), with the Vascular Health and Risk Management 2007:3(6) 811
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binding concentrations being independent over the range of 
10–500 ng/ml (Azizi et al 2006).
Interactions with other drugs
Aliskiren is not metabolized by cytochrome P450 and is not 
bound extensively to blood proteins therefore having a low 
potential for drug interactions.
It has been shown that multiple doses of aliskiren 
have no detectable effects on the pharmacodynamics or 
pharmacokinetics of a single dose of warfarin (Dieterle et al 
2004). Aliskiren shows no clinically relevant pharmacokinetic 
interactions with lovastatin, atenolol, celecoxib, or cimetidine 
in healthy male volunteers (Dieterle et al 2005). No interac-
tions with digoxin were observed in a pharmacokinetic study 
in 22 healthy volunteers (Dieterich et al 2006).
With regard to other antihypertensive medication, phar-
macokinetic interactions between aliskiren 300 mg and 
valsartan (320 mg), hydrochlorthiazide (HCTZ; 25 mg), 
amlodipine (10 mg) and ramipril (10 mg) have been studied 
in healthy subjects and no clinically relevant effects were 
shown (Vaidyanathan et al 2006).
Pharmacodynamic properties
Aliskiren is a highly potent inhibitor of human renin in 
vitro (IC50 = 0.6 nmol/L), this compares favourably with 
the earlier renin inhibitor compounds. Thus, the IC50 for 
enalkiren (A-64662) is 14 nmol/L (Rongen et al 1995), IC50 
for remikiren (Ro 42-5892) and zankiren (A-72517) are 
0.8 nmol/L and 1.1 nmol/L, respectively (Kleinbloesem et al 
1993; Menard et al 1995). Aliskiren shows high speciﬁ  city for 
human renin, with almost no inhibitory effect against other 
aspartic peptidases such as cathepsin D and pepsin. Although 
aliskiren also exhibits high afﬁ  nity for primate renin, it is 
signiﬁ  cantly less active against renin from dog, rat, rabbit, pig 
and cat (Wood et al 2003). This high potency for human renin 
compensates for the relatively low oral bioavailability of the 
drug. Renin displays high speciﬁ  city for its substrate and this 
species speciﬁ  city complicates the preclinical experimental 
studies with renin inhibitors. Special transgenic model that 
over-expresses both renin and angiotensinogen (ie, double 
transgenic rats) has been developed and has provided an 
alternative to primate models for the evaluation of renin 
inhibitors (Ganten et al 1992; Fukamizu et al 1993).
Pre-clinical and clinical studies have shown that aliski-
ren effectively inhibits RAAS, along with dose-dependent 
decrease in BP. In a double-blind, randomised, crossover 
study in normotensive volunteers (n = 18), aliskiren was 
administered in two oral doses (either 40 mg and 80 mg or 
160 mg and 640 mg once daily) and compared to enalapril 
20 mg/day, or placebo (Nussberger et al 2002). Aliskiren 
dose-proportionally decreased PRA and plasma Ang I and 
Ang II concentrations. Compared with placebo, the high-
est dose of aliskiren reduced plasma Ang II by about 80%, 
although the plasma concentration of renin rose by more 
than ten times. Inhibition was still signiﬁ  cant after repeated 
dosing, with maximal decreases in Ang II levels by 89% and 
75% on days 1 and 8, respectively. The inhibitory effects of 
aliskiren (160 mg) on Ang II were comparable to the effects 
of enalapril (20 mg). Decreases in plasma and urinary aldo-
sterone levels were detected with aliskiren at daily doses of 
80 mg or more but not at 40 mg (Nussberger et al 2002).
The effects of aliskiren on plasma renin activity (PRA) 
were assessed in an open-label, 8-week dose escalation 
study in patients with mild-to-moderate essential hyperten-
sion (n = 8). Aliskiren, 75 mg for 4-weeks, reduced PRA to 
34 ± 7% of baseline levels, with 4-weeks of further treatment 
with 150 mg of aliskiren giving an additional reduction to 
27 ± 6% of baseline activity (Wood et al 2003).
Importantly, the rapid rise in plasma immunoreactive 
renin levels observed following aliskiren administration, 
caused by the removal of the normal feedback inhibition 
of Ang II on renin release, did not compromise the ability 
of aliskiren to provide sustained PRA inhibition and BP 
lowering (Wood et al 2003). This is in accordance with the 
sustained inhibition of Ang II production observed over 
8-day period with once-daily oral administration of aliskiren 
in doses of 40–640 mg in healthy volunteers (Nussberger 
et al 2002).
In a small pilot trial with a four-period randomised 
crossover design, single doses of 300 mg aliskiren, 160 mg 
valsartan, the combination of 150 mg aliskiren plus 80 mg 
valsartan, or placebo were given to 12 male volunteers with 
mild sodium depletion (Azizi et al 2004). Aliskiren reduced 
PRA and plasma levels of Ang I and II for 48 h. Compared 
with valsartan, aliskiren more strongly stimulated the release 
of active renin into the circulation (about 10 times compared 
with about 15 times) while inhibiting PRA, and reduced the 
urinary aldosterone excretion for a longer period (8 vs 48 h). 
The effects of the combination of the lower doses of aliski-
ren and valsartan were similar to those of 300 mg aliskiren 
and larger than those of 160 mg valsartan. Aliskiren also 
blunted the valsartan-induced rise in plasma renin activity 
and in plasma concentration of angiotensin I and II (Azizi 
et al 2004). These ﬁ  ndings suggest that, at lower doses, renin 
inhibitors and angiotensin-receptor blockers might have 
synergistic effects on the renin system.Vascular Health and Risk Management 2007:3(6) 812
Allikmets
Similar ﬁ  ndings were obtained In 3 open-label studies 
in which BP was assessed with ambulatory measurement 
(O’Brien et al 2007). Aliskiren was administered to patients 
with mild-to-moderate hypertension in combination with 
hydrochlorothiazide (n = 23), ramipril (n = 21), or irbesartan 
(n = 23). Aliskiren (150 mg) alone signiﬁ  cantly inhibited 
plasma renin activity by 65% (p  0.0001) while ramipril and 
irbesartan monotherapy caused 90% and 175% increases in 
plasma renin activity, respectively. By contrast, when aliskiren 
was co-administered with hydrochlorothiazide, ramipril, or 
irbesartan, plasma renin activity did not increase but remained 
similar to baseline levels or was decreased, alon with improved 
24-hour blood pressure control (O’Brien et al 2007).
Clinical studies with aliskiren
in essential hypertensive patients
Early phase II trials with aliskiren compared the BP-lowering 
effects and safety of aliskiren with placebo, with losartan 
and irbesartan.
Aliskiren (at doses 37.5, 75, 150, and 300 mg once daily) 
and losartan (100 mg once daily) were compared in a 4-week 
trial in 226 patients with mild-to-moderate essential hyperten-
sion. Aliskiren showed dose-dependent reduction in BP, with 
the changes in patients getting 75–300 mg of aliskiren similar 
to those receiving 100 mg of losartan (Stanton et al 2003).
In a comparative trial with the ARB irbesartan, 652 hyper-
tensive subjects were randomized to receive either irbesartan 
(150 mg) or aliskiren (150, 300 and 600 mg). At a dose of 
150 mg, aliskiren was as effective as irbesartan (150 mg) in 
lowering blood pressure with similar safety and tolerability 
over the short term (Gradman et al 2005).
The BP-lowering effects of aliskiren (75, 150, or 300 
mg) alone or in combination with the ARB valsartan (80, 
160, or 320 mg) were compared in a multicenter, random-
ized, placebo-controlled, 8-week trial in 1123 patients with 
mild-to-moderate hypertension (Pool et al 2007). In an addi-
tional comparator arm, patients were receiving a combination 
of valsartan/hydrochlorothiazide (160/12.5 mg). The results 
indicated that co-administration of aliskiren and valsartan 
produced a greater antihypertensive effect than either drug 
alone, comparable in magnitude to the effect of valsartan/
hydrochlorothiazide, with similar tolerability to the compo-
nent monotherapies and to placebo (Pool et al 2007).
In subsequent trials, aliskiren has been compared with 
other antihypertensive drugs. Aliskiren (in doses 75 mg, 
150 mg, 300 mg once daily) was compared with HCTZ 
(in doses 6.25, 12.5, and 25 mg once daily), and with the com-
bination of the two agents in an 8-week placebo-controlled, 
factorial design trial in 2776 hypertensive patients (published 
so far only as an abstract). This study demonstrated that 
HCTZ signiﬁ  cantly potentiates the antihypertensive efﬁ  cacy 
of aliskiren. The greatest mean reduction in BP (21.2/14.3 
mmHg in systolic and diastolic BP, respectively) was 
observed with the combination of aliskiren 300 mg and 
HCTZ 25 mg. The responder rates for aliskiren monotherapy 
were betweem 51.9% (75 mg) and 63.9% (300 mg), and 
similar to those observed with HCTZ (Villamil et al 2006).
Data for safety and efﬁ  cacy of aliskiren over long-term 
use has recently become available. Thus, the efﬁ  cacy of 
aliskiren with optional addition of HCTZ was studied in a 
12-month open-label study (Sica et al 2006; published so far 
only as an abstract). Patients with mild-to-moderate essential 
hypertension were randomized to aliskiren 150 mg (n = 1178) 
or 300 mg (n = 773) once daily. Dose titration (aliskiren 
150 mg titrated to 300 mg) or addition of HCTZ (12.5 mg 
titrated to 25 mg if required) to aliskiren 300 mg was permit-
ted in patients with BP 140/90 mmHg after Month 2. A 
subgroup of patients remaining on aliskiren monotherapy at 
Month 11 were randomized to continued aliskiren (n = 132) 
or placebo (n = 129) during a 4-week double-blind with-
drawal phase. In total, 868 patients (45%) required addition 
of HCTZ, the BP reductions at study end were comparable 
in these patients (BP reduction of 18.7/12.1 mmHg) and 
the patients who had responded adequately to aliskiren 
monotherapy (BP reduction of 17.4/13.3 mmHg). Following 
treatment withdrawal, BP rose gradually with no evidence 
of rebound (Sica et al 2006).
Rebound hypertension has not emerged as a problem 
with aliskiren. Theoretically it is conceivable that long-term 
renin-inhibition therapy could induce pharmacologic toler-
ance with renin hypersecretion as well as the phenomenon 
of rebound hypertension after abrupt cessation of chronic 
therapy. However, clinical experience with aliskiren does 
not conﬁ  rm this, as shown in the long-term study reported 
recently by Sica et al 2006. In another study in 672 patients 
with mild-to-moderate essential hypertension, aliskiren with-
drawal after 8-week therapy (in doses 150, 300 or 600 mg) 
was not associated with blood pressure or PRA rebound, 
despite elevated plasma renin concentration at the time of 
withdrawal, BP and PRA remained suppressed for 2-weeks 
after discontinuation of therapy (Herron et al 2006).
Recently, Weir et al (2006) have reported a pooled 
analysis of data from 8 randomized multicenter studies with 
aliskiren, including 8570 patients with mild to moderate 
hypertension (published so far only as abstract). Treatment 
durations ranged from 6 to 52-weeks. The analysis showed Vascular Health and Risk Management 2007:3(6) 813
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that aliskiren as monotherapy effectively reduces blood pres-
sure in a dose-dependent fashion in doses of 75–600 mg, its 
effect was similar regardless of age or gender.
In summary, these clinical studies show that once-daily 
administration of aliskiren effectively lowers BP, being at 
least as effective as or possibly more effective than standard 
doses of established ACE inhibitors and ARBs. The long 
half-life of aliskiren can be expected to provide more reliable 
continuous BP control through the morning surge of BP that is 
known to be associated with increased cerebrovascular events 
(Kario et al 2003). Also, aliskiren possesses synergistic poten-
tial when combined with a thiazide diuretic, an ACE inhibitor, 
a calcium antagonist, and possibly also with an ARB.
Target organ protection
with aliskiren
There is considerable evidence that inhibition of RAAS 
in essential hypertension is associated with prevention of 
cardiovascular complications (Dahlöf et al 2002, 2005; 
Julius et al 2004). However, in all these studies (and several 
others), the interpretation of the results has been difﬁ  cult with 
regard to identifying the beneﬁ  ts that go beyond those of BP 
reduction per se. Moreover, it has been suggested that blood 
pressure lowering is the major determinant of cardiovascular 
events in primary and secondary prevention trials and the dif-
ferences in outcomes can be ascribed to small differences in 
achieved systolic blood pressure (Staessen et al 2005; Wang 
et al 2005). Similarly, a recent meta-analysis of 127 clinical 
trials questioned the speciﬁ  c renoprotective effects of ACE 
inhibitors and ARBs beyond the effect related to blood pres-
sure lowering (Casas et al 2005).
However, even though the underlying mechanisms of 
achieving cardiovascular protection may not be completely 
understood, establishing a new antihypertensive drug as a 
valuable addition to current therapeutic options requires proof 
of beneﬁ  cial effects on mortality and morbidity. There is no 
long-term data available yet for aliskiren from studies with 
hard endpoints, but certain characteristics of the drug may 
point to cardioprotective and renoprotective properties.
The potential renoprotective effects of renin inhibitors were 
suggested already based on the studies with the earlier com-
pounds. Studies on renal vasodilation with enalkiren and zankiren 
showed that renin inhibitors induce renal vasodilation to a greater 
extent than ACE inhibitors, despite the expectation that ACE 
inhibition might be superior due to additionally inducing vaso-
dilation through kinin generation (Hollenberg et al 1998). These 
studies indicate that renin inhibitors might confer renoprotection 
possibly to larger extent than the ACE inhibitors.
Pilz et al studied aliskiren in relation to target-organ damage 
in the double transgenic rat model comparing the effects of 
aliskiren (0.3 mg/kg/day and 3 mg/kg/day) and valsartan (1 
mg/kg/day and 10 mg/kg/day) with no treatment (Pilz et al 
2005). Both aliskiren doses and the high valsartan dose lowered 
blood pressure and albuminuria more effectively than the low 
valsartan dose. Aliskiren and valsartan in high dose ameliorated 
markedly left ventricular hypertrophy. After 3-weeks, none 
of the untreated rats had survived, compared with 74% of the 
low-dose valsartan group, and 100% in all other groups (ie, 
high-dose valsartan and both aliskiren doses). In this animal 
model, renin inhibition therefore compared favourably with 
AT1-receptor blockade in reversing target-organ damage.
It has been speculated that direct inhibition of renin 
might have further advantage in cardiovascular protection 
by preventing activation of speciﬁ  c renin receptors (Azizi 
et al 2006). The renin receptor was identiﬁ  ed in 1996 in 
the glomerular mesangium cells (Nguyen et al 1996), the 
receptor is also present in the subendothelium of coronary 
and renal arteries. Renin was found to bind to this receptor 
with high afﬁ  nity, but binding of renin to this receptor was 
not attenuated by renin inhibitors, indicating that the renin 
catalytic site is distinct from the receptor binding site. It 
was further elucidated that binding of renin to this receptor 
resulted in signiﬁ  cant increase in its catalytic efﬁ  ciency in 
Ang I formation (Nguyen et al 2002). Receptor-bound renin 
will also induce a series of intracellular events that are distinct 
from the generation of Ang II. Moreover, this receptor also 
binds prorenin that, when bound to the receptor, would have 
renin-like action. Prorenin has been shown to be a powerful 
predictor of microvascular complications in diabetes mellitus, 
although the exact mechanism of this deleterious effect has 
not been elucidated (Fisher and Hollenberg 2005). It could 
be speculated that the activation of the renin receptor, in 
combination with the increased catalytic activity, might play 
a role in the pathogenesis of vascular complications, pointing 
to an attractive therapeutic potential for renin inhibition.
Tolerability and safety
Aliskiren has been shown to be well tolerated in healthy sub-
jects and in patients with hypertension, when given as single 
and multiple oral doses. The incidence of adverse events with 
aliskiren and the number of study discontinuations as a result of 
adverse events during aliskiren treatment have been relatively 
low and were similar to results obtained in patients treated with 
wither placebo. The most common adverse effects reported 
were fatigue, headache, dizziness and diarrhoea (Stanton et al 
2003, Gradman et al 2005; Weir et al 2006).Vascular Health and Risk Management 2007:3(6) 814
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No dose-dependent increase in the number of adverse 
effects and no signiﬁ  cant abnormalities in laboratory param-
eters have been observed with aliskiren doses up to 300 mg 
(Stanton et al 2003; Weir et al 2006). However, higher doses 
of aliskiren (600 mg) seem to be associated with higher rate 
of diarrhoea when compared to placebo. In the meta-analysis 
by Weir et al (published so far only as abstract), the incidence 
of diarrhoea with aliskiren 600 mg was 9.5% versus 1.2% 
in the placebo group, there was no increase with aliskiren 
doses of 150 mg or 300 mg (1.2% and 2.3% respectively), 
and diarrhoea was not associated with patient discontinua-
tions (Weir et al 2006).
Aliskiren is a highly selective inhibitor of the RAS and does 
not interfere with the metabolism of bradykinin or substance 
P; therefore side-effects such as cough or angioedema that 
occur with ACE inhibitors are not likely to occur with aliskiren 
treatment. Aliskiren’s side effect proﬁ  le is rather comparable 
to that of ARBs (ie, similar to that of a placebo).
Aliskiren was well tolerated in patients with hepatic 
imparment (Vaidyanathan et al 2007). This open-label, 
nonrandomized, single-center, parallel-group study com-
pared the pharmacokinetics and safety of a single 300 
mg oral dose of aliskiren in patients with mild, moderate, 
or severe hepatic impairment to that in healthy subjects. 
Pooled analysis across subgroups was performed, with 
no signiﬁ  cant differences detected between patients with 
hepatic impairment and healthy subjects in aliskiren 
AUC0–∞ (ratio of geometric means, 1.12; 90% conﬁ  dence 
interval, 0.85, 1.48) or Cmax (mean ratio, 1.19; 90% con-
ﬁ  dence interval, 0.84, 1.68). Also, there was no correla-
tion between severity of hepatic impairment and either 
AUC0–∞ or Cmax. In conclusion, hepatic impairment had 
no signiﬁ  cant effect on the pharmacokinetics of aliskiren 
following single-dose administration, and dosage adjust-
ment is unlikely to be needed in patients with liver disease 
(Vaidyanathan et al 2007).
Although aliskiren appears to be safe, additional data 
would be needed to assess the effects of aliskiren on renal 
function and biochemistry, especially serum potassium 
levels in patients with renal impairment, heart failure and 
diabetes mellitus (Azizi et al 2006). The potential hazards 
of a complete RAAS inhibition with combination treatment 
(aliskiren combined with ACE inhibitor and/or ARB) require 
careful evaluation, especially in situations in which blood 
pressure and renal function are renin dependent (such as in 
elderly or salt-depleted patients), in patients receiving COX 
inhibitors, patients with renal artery stenosis and patients 
placed under anaesthesia (Azizi et al 2006).
In summary, aliskiren appears to be well tolerated and 
safe based on the available clinical data. Future studies 
should further conﬁ  rm the beneﬁ  cial side-effect proﬁ  le of 
aliskiren in speciﬁ  c patient populations such as patients with 
renal impairment or heart failure. The potential hazards of a 
complete RAAS inhibition when using aliskiren in combi-
nation with ACE inhibitors or ARBs need to be evaluated, 
especially in populations in whom BP and renal function are 
renin dependent, such as elderly, salt-depleted patients and 
patients with renal artery stenosis.
Conclusion
Aliskiren offers a promising new approach to the blockade 
of the RAS. It is the ﬁ  rst representative of a new class of 
non-peptide, low molecular weight, orally active transition-
state renin inhibitors. Its high potency against human renin 
compensates for its relatively low absolute bioavailability, 
its long half-life makes it suitable for once daily administra-
tion. Aliskiren is effective in reducing blood pressure and is 
well tolerated, with a side-effect proﬁ  le similar to placebo 
or ARBs. It exhibits synergistic effects when combined with 
drugs that lead to a reactive increase in the plasma renin 
activity, such as diuretics, ACE inhibitors or ARB. Aliskiren 
has demonstrated target organ protection in animal models 
and in clinical trials, future studies must show whether these 
properties translate into beneﬁ  cial effects on long-term mor-
bidity and mortality.
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